INTRODUCTION
Innate immunity is an evolutionarily ancient mechanism for rapidly sensing and responding to potential pathogens. Innate immune mechanisms are induced in response to bacterial molecular signatures. A variety of bacterial surface components and secreted molecules have been demonstrated to bind to specific host receptors. 1 Among the best characterized and most important of these signals is lipopolysaccharide (LPS), the major component of the Gram-negative bacterial envelope. LPS consists of three distinct structural elements -O-antigen, core, and lipid A. Both O-antigen and core are composed of polysaccharide chains, whereas lipid A or endotoxin is composed of fatty acids and phosphate groups attached to a central glucosamine dimer. 2 The structure of lipid A varies between Gram-negative bacteria of different species. The environmental bacterium Pseudomonas aeruginosa is an opportunistic pathogen of humans and chronically infects patients with cystic fibrosis. In such infections, P. aeruginosa modifies its lipid A structure, a process that can also be induced in vitro by growth under magnesium-limiting conditions. 3 P. aeruginosa cystic fibrosis-specific lipid A modifications include the addition of palmitate and aminoarabinose. These modifications result in maintenance of P. aeruginosa outer membrane integrity, and resistance to host innate immune killing. [3] [4] [5] Host recognition of lipid A is mediated by the Toll-like receptor 4 (TLR4) complex. 6, 7 This complex consists of the TLR4 receptor and two co-receptors -MD-2 (required for TLR4 function) 8, 9 and CD14 (a high affinity GPI-linked LPS binding protein). 10 Interaction of lipid A with the TLR4 receptor complex triggers a phosphorylation cascade (via TRAF6 and the signaling kinases NIK and IKK) that results in the phosphorylation and subsequent degradation Lipid A is the pro-inflammatory component of bacterial lipopolysaccharide, the major surface component of Gram-negative bacteria. Gram-negative bacteria alter the structure of lipid A in response to specific environmental conditions including those found upon colonization of a host. The opportunistic pathogen Pseudomonas aeruginosa synthesizes a unique hexa-acylated lipid A containing palmitate and aminoarabinose during adaptation to the cystic fibrosis airway. Different lipid A species are observed in P. aeruginosa isolated from non-cystic fibrosis associated infections.
Here we report that P. aeruginosa isolates from the airway of a cystic fibrosis patient with severe pulmonary disease synthesized a novel hepta-acylated lipid A. Cystic fibrosis-specific P. aeruginosa lipid A modifications result in resistance to host antimicrobial peptides and increased recognition by human Toll-like receptor 4 (TLR4). Using P. aeruginosa lipid A with different levels of acylation, we identified a 222 amino acid region in the extracellular portion of human TLR4 that is required for the differential recognition of cystic fibrosis-specific lipid A. P. aeruginosa adaptation to the human airway may, therefore, play a fundamental role in the progressive lung damage associated with cystic fibrosis.
of IkB and translocation of NF-kB to the nucleus. Nuclear NF-kB drives the transcription of a variety of gene products involved in the host inflammatory response.
Our laboratory previously showed that human cells and human TLR4 (huTLR4) receptor, but not murine cells or murine TLR4 (muTLR4) receptor, discriminated between different lipid A structures of P. aeruginosa. 6 Differential recognition of lipid A variants was mediated by a small hypervariable region in the extracellular portion of the TLR4 receptor. This study reports the identification of a region in the huTLR4 receptor that includes the hypervariable region and that can confer human discriminatory properties on a chimera of the mouse and human TLR4 receptors. We also describe a novel lipid A structure in P. aeruginosa isolates from a cystic fibrosis patient with severe pulmonary disease, and propose a biosynthetic pathway for cystic fibrosis-specific LPS structure.
MATERIALS AND METHODS

Bacterial culture conditions, LPS preparations and reagents
Bacterial strains were grown in Luria broth supplemented with 1mM magnesium. LPS and lipid A were isolated and analyzed using matrix-assisted laser desorption ionization mass spectrometry (MALDI-TOF) and gas chromatography as described previously. 5 LPS preparations were repurified by phenol extraction to eliminate trace amounts of lipoprotein. 11 Escherichia coli LPS (O111:B4) was purchased from Sigma.
HEK-293 cell transfections and stimulation
Transfections and stimulation experiments were performed as previously described 12 with the following modifications. Briefly, 4 x 10 4 HEK-293 cells were plated in 96-well plates the day before transfection. The following amounts of DNA were transfected per well: ELAM-Luc, 0.01 mg; Renilla-Luc, 0.0003 mg; huCD14, 0.0025 mg; huMD-2, 0.0025 mg; huTLR4, 0.002 mg; muTLR4, 0.00025 mg; mh222m, 0.0005 mg; hm82h, 0.0015 mg. Total DNA per well was normalized to 0.05 mg by the addition of empty vector. Cells were washed 3 h post-transfection and stimulated 20-24 h later in the presence of 10% non-heat inactivated fetal bovine serum as a source of LPS-binding protein (LBP). Relative Light Units were obtained by normalizing the firefly luciferase value (ELAM-Luc) to the Renilla luciferase value (b-actin-Renilla Luc) subtracting the unstimulated value, and multiplying by 100. Error bars indicate SD of triplicate wells.
TLR4 receptor constructs
Hemagglutinin (HA) epitope-tagged TLR constructs were generated and purified as previously described. 12 huTLR4 consists of amino acids 27-839 (amino acids 1-26 are the signal sequence) and muTLR4 consists of amino acids 26-835. hm82h consists of huTLR4 amino acids 27-286, muTLR4 amino acids 285-366, and huTLR4 amino acids 369-839. mh222m consists of muTLR4 amino acids 26--176, huTLR4 amino acids 178-399, and muTLR4 amino acids 398-835. huCD14 was constructed by cloning the human CD14 ORF into pCDNA3.1 (Invitrogen).
RESULTS AND DISCUSSION
A unique hexa-acylated lipid A in P. aeruginosa isolates from the cystic fibrosis airways Most children with cystic fibrosis develop P. aeruginosa airway infection by 3 years of age. 13 In nearly all cystic fibrosis patients, death results from progressive lung damage due to the inflammatory response to unremitting P. aeruginosa infection. 14 LPS isolated from P. aeruginosa clinical isolates obtained from young children (< 3 years of age) with cystic fibrosis and an older patient with mild pulmonary disease contained a penta-acylated ( Fig. 1A) and a unique hexa-acylated form of lipid A. The cystic fibrosisspecific hexa-acylated lipid A demonstrated the addition of both palmitate (C16 fatty acid) and aminoarabinose (Fig.  1B) . A different lipid A structure was found in LPS from P. aeruginosa isolated from the environment, bloodstream or urinary tract, or from individuals with another chronic lung disease, bronchiectasis (Fig. 1C) . LPS from laboratoryadapted strains of P. aeruginosa grown in conventional bacterial culture media contained only the penta-acylated LPS structure (Fig. 1A) . Compared to this penta-acylated LPS, the hexa-acylated form was shown to stimulate a more robust pro-inflammatory response in both macrophages and endothelial cells, suggesting that the acylation state affects LPS-mediated responses. 5, 6 
Identification of a region in human TLR4 that distinguishes between P. aeruginosa lipid A structures
In response to both hexa-and penta-acylated P. aeruginosa LPS (Fig. 1A,B ), mouse macrophages (RAW 264.7) produced equivalent amounts of TNF-a and transfected cells expressing muTLR4 stimulated equivalent NF-kB activity, respectively. In contrast, human monocytic cells (THP-1) and transfected cells expressing huTLR4 responded preferentially to the more highly acylated LPS. 6 For the muTLR4 receptor, the ability to robustly recognize the penta-acylated lipid A was localized to an 82 amino acid hypervariable domain (muTLR4 amino acids 285-366) in the extracellular portion of murine receptor. 6 The corresponding chimeric TLR4 receptor containing this region from the human receptor (huTLR4 amino acids 287-368) was non-functional, and did not mediate a response to any LPS preparation tested even though the protein was detected in cell lysates.
Therefore, to determine the region of the huTLR4 receptor that is responsible for the lack of recognition of P. aeruginosa penta-acylated lipid A, additional chimeric murine/human receptors were constructed. In these chimeras, larger portions of the huTLR4 extracellular domain (222 residues, amino acids 178-399 and 330 residues, amino acids 287-616) were exchanged with muTLR4. Plasmids expressing these chimeras ( Fig. 2A) were co-transfected into HEK-293 cells along with plasmids expressing the human MD-2 and CD14 co-receptors, an NF-kB inducible ELAM-Luc reporter construct and a transfection control reporter. Cells expressing Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4 397 muTLR4 or a chimeric receptor (hm82h) containing an 82 amino acid region of muTLR4, mediated NF-kB activation in response to both penta-and hexa-acylated LPS (Fig. 2B,D) . In contrast, cells transfected with huTLR4 responded poorly to penta-acylated LPS, requiring nearly 100-fold more of this LPS relative to hexa-acylated LPS (Fig. 2C) . Cells expressing the chimeric receptors encoded by mh222m or mh330m also responded poorly to the penta-acylated LPS preparations ( Fig. 2E, data not shown) . E. coli LPS was a potent stimulator of both huTLR4 and muTLR4 and the chimeric receptors ( Fig. 2B-E) . These results demonstrate that for both muTLR4 and huTLR4, a region centered on an 82 amino acid hypervariable region determines whether the receptor can discriminate between the two forms of P. aeruginosa lipid A.
A unique hepta-acylated lipid A in P. aeruginosa isolates from a cystic fibrosis patient with severe pulmonary disease
Lomgitudinal P. aeruginosa clinical isolates from a cystic fibrosis patient (12-18 years of age) with severe pulmonary disease synthesized yet another lipid A structure (Fig. 1D) . Lipid A extracted from severe patient clinical isolates displayed a hepta-acylated structure consisting of four fatty acids (two 3-OH-C10 and two 3-OH C12) attached to the glucosamine backbone with three secondary 'piggy back' fatty acids (C12, 2-OH C12 and C16). The hepta-acylated lipid A species differed from the hexa-acylated lipid A (Fig.  1B) by the presence of a 3-OH C10 fatty acid at the 3 position on the glucosamine backbone.
Proposed biosynthesis of cystic fibrosis-associated P. aeruginosa lipid A structures
The results discussed above, together with previously published P. aeruginosa lipid A structural data, 15, 16 suggest a pathway for the generation of cystic fibrosis-specific lipid A structures (Fig. 3) . P. aeruginosa lipid IVA is acylated by the addition of laurate (C12) generating the non-cystic fibrosis species of lipid A (m/z 1419, Fig. 1C ). Interestingly, analysis of lipid A from P. aeruginosa isolates associated with non-cystic fibrosis infections (blood, eye and bronchiectasis) revealed only this penta-acylated form of lipid A (m/z 1419, Fig. 1C ). This penta-acylated structure is further acylated by the addition of 2-hydroxyl laurate (2-OH C12) to generate a hexa-acylated species of lipid A, m/z 1616. Recently, enzymatic activity has been identified in P. aeruginosa that removes a single ester-linked hydroxy fatty acid residue at the 3 position of the lipid A backbone. 17 Such a deacylase activity acts on the hexa-acylated lipid A (m/z 1616) to generate the penta-acylated species associated with cystic fibrosis (m/z 1447, Fig. 1A) . This penta-acylated species of lipid A can be palmitoylated (addition of C16) to generate the cystic fibrosis-specific hexa-acylated species (m/z 1685, Fig. 1B ). In P. aeruginosa isolates from a cystic fibrosis patient with severe pulmonary disease, deacylase enzymatic activity is hypothesized to be inactive in order to generate the hepta-acylated species (m/z 1854, Fig. 1D ). Finally, P. aeruginosa lipid A (Fig. 1A,B) can also be modified by the addition of aminoarabinose(s) to the phosphate residues at either the 1 or 4¢ position.
CONCLUSIONS
This study shows that clinical isolates of P. aeruginosa from patients with cystic fibrosis have the ability to modulate their lipid A structures. These structural modifications ultimately result in altered host innate immune recognition and suggest that humans have evolved the ability to discriminate between very similar LPS structures via a hypervariable region in the TLR4 receptor. Further studies are required to understand better the molecular mechanisms and details of microbial LPS remodeling. This knowledge should be useful in the development of new antimicrobials by targeting innate immunity resistance mechanisms specifically induced in microorganisms within host microenvironments, such as the airways of patients with cystic fibrosis.
